Technical Analysis for OPK - OPKO Health Inc.

Grade Last Price % Change Price Change
grade F 1.96 2.08% 0.04
OPK closed up 2.08 percent on Friday, May 24, 2019, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical OPK trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 2.08%
New 52 Week Low Weakness 2.08%
Wide Bands Range Expansion 2.08%
Oversold Stochastic Weakness 2.08%
180 Bearish Setup Bearish Swing Setup -1.01%

Older signals for OPK ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimer's disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; point-of-care diagnostic tests to detect prostate specific antigen; and laboratory developed tests comprising 4Kscore test for the detection of prostate cancer. It also operates OURLab, a full-service medical laboratory specializing in urologic pathology. In addition, the company is developing CTAP101 Capsules to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Fermagate Tablets to treat hyperphosphatemia in end-stage renal disease patients on chronic hemodialysis. Further, it is developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, such as cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate that has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. Additionally, the company develops and produces specialty active pharmaceutical ingredients; offers ophthalmic and other pharmaceutical products; and provides cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones. It operates in the United States, Chile, Mexico, Israel, and Spain. OPKO Health, Inc. is based in Miami, Florida.
Health Cancer Cancers Chemotherapy Clinical Trial Pharmaceutical Industry In China Prostate Cancer Alzheimer's Disease Non Small Cell Lung Cancer Influenza Medical Tests Diagnostic Tests Active Pharmaceutical Ingredients Antibiotics Asthma Chronic Kidney Disease Pancreatic Cancer Molecular Diagnostics End Stage Renal Disease Hemodialysis Infectious Disease Autoimmune Disease Nausea Metabolic Disorders Vomiting Cardiovascular Products Heart Disease Chronic Obstructive Pulmonary Diseases Organ Failure Secondary Hyperparathyroidism Hyperphosphatemia Such As Cancer
Is OPK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.4
52 Week Low 1.9
Average Volume 4,635,533
200-Day Moving Average 3.3951
50-Day Moving Average 2.3598
20-Day Moving Average 2.156
10-Day Moving Average 2.008
Average True Range 0.1155
ADX 38.59
+DI 10.0192
-DI 26.691
Chandelier Exit (Long, 3 ATRs ) 2.1535
Chandelier Exit (Short, 3 ATRs ) 2.2465
Upper Bollinger Band 2.5213
Lower Bollinger Band 1.7907
Percent B (%b) 0.23
BandWidth 33.886827
MACD Line -0.1251
MACD Signal Line -0.1169
MACD Histogram -0.0082
Fundamentals Value
Market Cap 1.1 Billion
Num Shares 559 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -13.07
Price-to-Sales 3.13
Price-to-Book 1.76
PEG Ratio -2.91
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.04
Resistance 3 (R3) 2.03 2.00 2.02
Resistance 2 (R2) 2.00 1.98 2.00 2.02
Resistance 1 (R1) 1.98 1.97 1.99 1.99 2.01
Pivot Point 1.95 1.95 1.96 1.95 1.95
Support 1 (S1) 1.93 1.93 1.94 1.94 1.91
Support 2 (S2) 1.90 1.92 1.90 1.90
Support 3 (S3) 1.88 1.90 1.90
Support 4 (S4) 1.89